OtoImmune

About OtoImmune

OtoImmune is a Cambridge-based precision immunology company working to transform how immune-related conditions, including autoimmune diseases and Long COVID, are understood, detected, and managed. Many of these conditions involve years of uncertainty, fragmented care, and delayed diagnosis. OtoImmune aims to address these gaps by generating clearer, earlier insight into immune health. The company combines molecular diagnostics, digital health technologies, and advanced data analysis to better understand immune function and disease progression. In addition to developing proprietary tests and biomarker discovery programmes, OtoImmune collaborates with clinics, clinicians, biotechnology companies, and pharmaceutical partners to translate scientific advances into practical tools for research and patient care. Its consumer platform, mOI Health (pronounced “mwah”), provides personalised immune insights by integrating health testing, symptom tracking, medical history, and lifestyle data within a single secure environment. This approach helps individuals understand patterns in their health and supports more informed engagement with healthcare providers. Founded by a team with both scientific expertise and lived experience of immune-related conditions, OtoImmune seeks to reduce diagnostic delays, improve coordination of care, and support a shift from reactive treatment toward earlier, more personalised approaches to health management.